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CLINICAL RESEARCH
Valvular heart disease
Prosthesis-patient mismatch after transcatheter
aortic valve implantation with the Medtronic-
Corevalve bioprosthesis
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Aims Prosthesis-patient mismatch (P-PM) is an important determinant of morbidity and mortality following open aortic
valve replacement. The aims of this study were to report its incidence and determinants following transcatheter
aortic valve implantation (TAVI) with the Corevalve bioprosthesis, which have—thus far—not been described.
Methods
and results
Patients with severe calcific aortic stenosis received TAVI with the Corevalve bioprosthesis via transfemoral route.
Following TAVI, moderate P-PM was defined as indexed aortic valve effective orifice area (AVAi) 0.85 cm2/m2
and severe P-PM as AVAi 0.65 cm2/m2. Clinical, echocardiographic, and procedural factors relating to P-PM
were studied. Optimal device position was defined on fluoroscopy as final position of the proximal aspect of the
Corevalve stent frame 5–10 mm below the native aortic annulus. Between January 2007 and January 2009, 50 con-
secutive patients underwent TAVI in a single centre with the Corevalve bioprosthesis. Mean age was 82.8 years (SD
5.9; 70–93) and 48% were male. P-PM occurred in 16 of 50 cases (32%). Optimal position was achieved in 50% of
cases. P-PM was unrelated to age, annulus size, LVOT size, Corevalve size, aortic angulation, ejection fraction, and sex.
It was inversely correlated to optimal position (Spearman rho r ¼ 20.34, P ¼ 0.015). Those with optimal positioning
had a 16% incidence of P-PM relative to 48% of those with suboptimal positioning (Pearson x2 P ¼ 0.015).
Conclusion The incidence of P-PM following TAVI with the Corevalve bioprosthesis is compared favourably with that seen after
AVR with conventional open stented bioprostheses and its occurrence is influenced by device positioning.
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Keywords Prosthesis-patient mismatch † Patient-prosthesis mismatch † Transcatheter aortic valve implantation (TAVI) †
Percutaneous aortic valve replacement (PAVR) † Medtronic-Corevalve
Introduction
Prosthesis-patient mismatch (P-PM) was first conceived by Rahim-
toola in 1978.1 Its conception was based on the premise that no
valve prosthesis can fully approximate native valvular function
and as such all valvular prostheses have at least mild P-PM. Sub-
sequently, P-PM—when moderate or severe—has been shown
to be an important determinant of morbidity, exercise capacity,
and mortality following conventional open aortic valve replace-
ment, occurring in 20–70%2,3 of patients undergoing conventional
open aortic valve replacement. Transcatheter aortic valve implan-
tation (TAVI) has shown great promise in the treatment of severe
aortic stenosis (AS) in patients regarded at high risk from or
inoperable by conventional surgery.4–11 The incidence and deter-
minants of P-PM following TAVI has not been described. We
sought to investigate the incidence of the phenomenon of P-PM
after TAVI with the Medtronic-Corevalve bioprosthesis, which is
designed for supra-annular positioning (Figure 1).6 We also hypoth-
esized that its occurrence could be predicted by clinical, echocar-
diographic, and procedural factors.
Methods
The study complies with the Declaration of Helsinki: a locally
appointed Ethics Committee has approved the research protocol
and informed consent was obtained from all subjects.
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Clinical and anatomical selection criteria were in accord with the
published investigational study for the third generation (18F) Corevalve
device.6,7 Patients were recruited in a single centre and received
transcatheter aortic valve implantation (TAVI) with the Medtronic-
Corevalve bioprosthesis via transfemoral route. All patients had
severe calcific aortic stenosis (aortic valve area, AVA , 1 cm2 or
BSA indexed AVA, AVAi, 0.6 cm2/m2). They were symptomatic, con-
sidered at high risk from, or inoperable by, conventional surgery, had
annuli of 20–27 mm and suitable peripheral vasculature (femoral
artery diameter .6 mm). Patients with annuli of 20–23 mm received
a 26 mm prosthesis (sized by its left-ventricular or ‘inflow’ diameter);
those with annuli of 23–27 mm received a 29 mm prosthesis. The
device was implanted as previously described.6,7
Echocardiographic aortic regurgitation (AR) was graded semiquanti-
tatively using an established integrative approach12 with parasternal
long-axis view observations: none (grade 0), trivial or mild (grade
1 þ ), moderate (grade 2 þ ), moderate–severe (grade 3 þ ), and
severe (grade 4 þ ).
The endpoint of prosthesis-patient mismatch (P-PM) was defined,
according to previous convention,3 as severe if the indexed aortic
valve area [AVAi ¼ (Effective Orifice Area/body surface area)] was
0.65 cm2/m2 and moderate if the AVAi was 0.85 cm2/m2 but
.0.65 cm2/m2. Effective orifice area was calculated using the continu-
ity equation (VTI method) and data derived from transthoracic echo-
cardiography pre- and post-device implantation. Specifically, native
LVOTd was measured on transthoracic echocardiography in the para-
sternal long-axis view in a selected zoomed mid-systolic frame, just
below the hinge points of visible leaflets perpendicular to the aortic
root wall; AVR LVOTd was measured in a zoomed mid-systolic
frame in the parasternal long-axis view, just below hinge points of
visible prosthetic leaflets, perpendicular to AVR long axis and from
inner edges of the stent. The native aortic annulus was measured on
transthoracic echocardiography in the parasternal long-axis view in
a selected zoomed mid-systolic frame precisely from hinge point to
hinge point. Candidate predictors (independent variables) of P-PM
studied included age, sex, annulus size, LVOT size, bioprosthesis size,
aortic angulation, and ejection fraction.
Depth of final device placement in the left-ventricular outflow tract
(LVOT) was also studied. This was measured using a final fluoroscopic
aortogram acquisition with the deployed bioprosthesis in a right
anterior oblique (RAO) projection that displayed the aortic valve in
optimal alignment with—as much as possible—all three leaflets
visible in the same plane. The depth of delivery was defined as the dis-
tance from the native aortic annular margin on the side of the non-
coronary cusp (leftward on the described projection) to—on the cor-
responding side—the most proximal edge (deepest in the left ventri-
cle) of the deployed stent-frame. The pre-dilatation (Nucleus)
balloon filmed in the same projection was used for calibration, its
markers 20 mm apart. Importantly, its proximal markers spanning
the LVOT were used for calibration, which is precisely the same vicin-
ity where the final depth of implantation of the prosthesis was
measured. Depth of delivery was also measured on transoesophageal
echocardiography for a selected cohort, for comparison to the
angiographic measure.
Since the trileaflet porcine pericardial valve is mounted onto the
nitinol stent-frame 12 mm above the left-ventricular edge of the
stent (Figure 1), ‘optimal’ placement of the valvar component in
the recommended supra-annular position was defined by the depth
of the left-ventricular edge of the stent-frame in the LVOT relative
to the annulus of the native non-coronary cusp of the aortic valve.
The ‘optimal’ depth of 5–10 mm below the native non-coronary
cusp as measured on fluoroscopy, would correlate to the prosthetic
valve lying 2–7 mm above the native annulus. All other depths of
delivery were defined as ‘suboptimal’.
To correct for any potential distortion in the stent frame, either true
or spurious, relative depth of implantation was derived from the
absolute depth as a percentage of the full final measured length of
the stent frame. As an optimal absolute depth of implantation of 5–
10 mm was stipulated, optimal relative depth of implantation was rep-
resented as 5–10 mm of the full expected stent frame length supplied
by the manufacturer. This proposed optimal absolute depth equates to
a relative depth of 9.1–18.2% of 55 mm for the smaller 26 mm inflow
Medtronic-Corevalve prosthesis (CRS-P3-640) and 9.4–18.9% of
53 mm for the larger 29 mm inflow prosthesis (CRS-P3–943).
Statistical methods
Statistical analysis was made using SPSS software (SPSS, Inc., Chicago,
IL, USA). Differences were assessed using a paired sample t-test for
normally distributed data or Wilcoxon signed rank two related
samples analyses for other distributions. For comparison of indepen-
dent non-parametric variables, a x2 statistic was used and for indepen-
dent normally distributed variables an independent samples t-test. For
correlations Pearson bivariate analysis with a two-tailed test for signifi-
cance was used for parametric variables and Spearman rho corre-
lations for non-parametric variables. Factors found to be related
univariately to P-PM were studied in a multivariate binary logistic
regression model.
Results
Between January 2007 and December 2008, 50 patients under-
went TAVI. Baseline demographics are shown in Table 1. Mean
age was 82.8 years (SD 5.9; 70–93) and mean logistic EuroSCORE
was 22.2% (SD 13.1; 5.27–76.26). Forty-eight percent were male.
Figure 1 Medtronic-Corevalve. (A) Supra-annular device. The
Medtronic-Corevalve transcatheter bioprosthesis is designed for
prosthetic supra-annular positioning (depicted in blue) within
the constrained portion (B) of the nitinol stent-frame. Within
the left-ventricular outflow tract is the forcefully expansile
portion of the stent-frame (C) which has a covered skirt to mini-
mize paraprosthetic aortic regurgitation. The aortic portion (A) is
designed to gently anchor the stent-frame to the aortic wall.
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Procedural results
There was one periprocedural death secondary to heart failure
aggravated by cardiac tamponade (2.9%) and subsequently a
further four deaths within 30 days of the procedure. These were
due to a subdural intracerebral haematoma following a fall, loss
of temporary pacemaker capture with underlying asystole after
successful implantation, an ischaemic stroke in a severely cachectic
patient, and a perioperative death attributable to a low output
state following an open surgical revision for severe paraprosthetic
AR. Median post-procedural time in hospital, in those surviving to
discharge, was 5 days (interquartile range 4–8).
Haemodynamic results
There were significant periprocedural reductions in peak (80.6+
29.9 to 15.9+5.6 mmHg, P, 0.001) and mean (48.0+18.4 to
8.1+ 3.3 mmHg, P, 0.001) transvalvular gradients by echocardio-
graphy. There were substantial increases in aortic valve areas calcu-
lated by continuity effective orifice areas using Doppler velocity time
integrals (CEOA VTI): 0.7+0.2 to 1.7+0.5 cm2, P, 0.001.
Aortic regurgitation
There were no cases of transvalvular AR. On post-procedural
transthoracic echocardiography, paravalvular AR was not present
in 16%, grade 1 in 76%, grade 2 in 4% and grade 3–4 in 4%
(Table 2). Optimal device position per se did not influence
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Table 2 Haemodynamic and functional data
Pre Post P-value
Peak aortic gradient, mmHg,
mean+ SD
80.6+29.9 15.9+5.6 ,0.001
Mean aortic gradient, mmHg,
mean+ SD
48.0+18.4 8.1+3.3 ,0.001
AVA, cm2, mean+ SD 0.7+0.2 1.7+0.5 ,0.001
AVAi, cm2/m2, mean+ SD 0.4+0.1 1.0+0.3 ,0.001
Prosthetic AVAi 0.85 cm2/
m2 (%)
— 16 (32) —
Prosthetic AVAi 0.8 cm2/
m2 (%)
— 14 (28) —
Prosthetic AVAi 0.65 cm2/
m2 (%)
— 1 (2) —
AR grade
0, n (%) 14 (28) 8 (16) P ¼ 0.196
1þ, n (%) 32 (64) 38 (76)
2þ, n (%) 3 (6) 2 (4)
3þ, n (%) 1 (2) 1 (2)
4þ, n (%) 0 1 (2)
Biplane LVEF, %, mean+ SD 49.9+13.5 55.5+9.4 0.001
Biplane LVEF 30%, n (%) 7 (14) 0 0.008
Biplane LVEF 40%, n (%) 15 (30) 6 (12) 0.005
Biplane LVEF 50%, n (%) 23 (46) 12 (24) 0.005
NYHA status
I, n (%) 0 27 (54) ,0.001
II, n (%) 24 (48) 16 (32)
III, n (%) 22 (44) 2 (4)
IV, n (%) 4 (8) 0
AVA, aortic valve area; AVAi, indexed aortic valve area; AR, aortic regurgitation;
LVEF, left-ventricular ejection fraction.
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Table 1 Baseline characteristics
(n 5 50)
Mean age, years+ SD 82.8+5.9
Male gender, n (%) 24 (48)
Diabetes, n (%) 9 (18)
Hypertension, n (%) 21 (42)
Atrial fibrillation, n (%) 14 (28)
Ischaemic heart disease, n (%) 23 (46)
Prior MI, n (%) 7 (14)
Prior CVA/TIA, n (%) 7 (14)
Prior CABG, n (%) 9 (18)
Prior PCI, n (%) 15 (30)
Prior permanent pacemaker, n (%) 4 (8)
Peripheral vascular disease 5 (10)
Dialysis 2 (4)
Creatinine .200 mmol/L 2 (4)
Any renal impairment (eGFR ,50 mL/min) 24 (48)
Pulmonary disease 16 (32)
Prior malignancy, n (%) 7 (14)
Active malignancy, n (%) 3 (6)
Declined outright for open surgery: 17 (34)
Multiple risk factors, log EuroSCORE .30 6 (12)
Severe respiratory disease 5 (10)
Porcelain aorta 3 (6)
Age .90 2 (4)
No contractile reserve on stress ECHO 1 (1)
Symptoms
Dyspnoea, n (%) 50 (100)
Angina, n (%) 34 (68)
Syncope, n (%) 7 (14)
Emergent case/cardiogenic shock 1 (2.0)
NYHA I, n (%) 0
II, n (%) 24 (48)
III, n (%) 22 (44)
IV, n (%) 4 (8)
Biplane LVEF, %, mean+ SD 49.7+13.5
Biplane LVEF 30%, n (%) 7 (14)
Biplane LVEF 40%, n (%) 15 (30)
Biplane LVEF 50%, n (%) 23 (46)
Logistic EuroSCORE, mean+ SD 22.2+13.1
Logistic EuroSCORE .20%, n (%) 25 (50)
Peak pressure gradient, mmHg, mean+ SD 79.7+30.4
Mean pressure gradient, mmHg, mean+ SD 47.4+18.7
Aortic valve area, cm2, mean+ SD 0.7+0.2
MI, myocardial infarction; CVA, cerebrovascular accident; TIA, transient ischaemic
attack; CABG, coronary artery bypass grafting; PCI, percutaneous coronary
intervention; LVEF, left-ventricular ejection fraction.
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degree of AR (Table 3), suggesting factors other than positioning
to be important in the pathogenesis of this phenomenon.
However, the incidence of very deep delivery (.15 mm) was
rare (n ¼ 2, 4%), and using a Spearman rho correlation, clinically
significant paravalvular AR (grade 2 or more on post-procedural
echocardiography) was related to very deep depth of delivery
(r ¼ 0.313, P ¼ 0.032).
Left-ventricular systolic function
and NYHA status
There was an acute improvement in biplane ejection fraction on
the pre-discharge echocardiogram, relative to baseline, from
49.9+12.6 to 55.5+ 9.4% (P ¼ 0.001). This improvement was
more marked in those with at least moderate LV impairment at
baseline (EF, 40%), EF increasing from a mean of 31.5 to 47.5%
(P ¼ 0.001).
For the 45 patients surviving beyond 30 days, NYHA status
improved from a mean of 2.58 at baseline to 1.44 pre-discharge
(P, 0.001). There was 1 case with a deterioration in NYHA
status (2%), 4 (8%) with no change, and 40 with an improvement
(80%) (Table 2).
Incidence and predictors of
prosthesis-patient mismatch
Prosthesis-patient mismatch occurred in 16/50 cases (32%)
(Table 4). It was unrelated to age, sex, native AV annulus dimension
(Figure 2), LVOT dimension, device size, aortic angulation, and
baseline biplane ejection fraction.
Depth of implantation was on average 10.5+3.4 mm, measured
fluoroscopically in all cases. Depth of implantation measured in 26
patients on transoesophageal echocardiography correlated well to
the fluoroscopic measure (Pearson correlation coefficient r ¼
0.728, P, 0.001).
Optimal position (defined here as 5–10 mm below the native
aortic annulus measured fluoroscopically) was inversely correlated
to P-PM (Spearman rho r ¼ 20.34, P ¼ 0.015). However, despite
this clear correlation optimal position was unrelated to AVA, BSA,
and AVAi per se, suggesting a nonlinear relationship between
optimal position and AVAi, with a degree of overlap between
optimal and suboptimal implants in the lower range of AVAi
which are not clinically significant (i.e. AVAi . 0.85 cm2/m2, not
P-PM, Figure 3). The variable of optimal relative depth of implan-
tation (depth of implantation as a proportion of measured stent
frame length) remained inversely correlated to P-PM (Spearman
rho correlation coefficient r ¼ 20.364, P ¼ 0.01), suggesting that
the data presented here for absolute depth is robust.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Differences between patients with optimal
and suboptimal Medtronic-Corevalve positioning
‘Optimal’
device position,
n5 25
‘Suboptimal’
device position,
n 5 25
P-value
Depth of
implantation,
cm (SD)
0.8 (0.1) 1.3 (0.3) ,0.001
Age, years (SD) 84.2 (4.9) 81.4 (6.5) 0.082
Male sex, n (%) 11 (44) 13 (52) 0.571
Annulus size, cm
(SD)
2.3 (0.2) 2.3 (0.2) 0.504
LVOT size, cm
(SD)
2.2 (0.3) 2.1 (0.3) 0.105
STJ size, cm (SD) 2.8 (0.5) 2.8 (0.4) 0.566
Aortic
angulation,
degrees from
midline (SD)
227.8 (10.5) 228.1 (10.3) 0.901
Prosthetic AVA,
cm2 (SD)
1.8 (0.5) 1.7 (0.5) 0.337
BSA, m2 (SD) 1.7 (0.2) 1.8 (0.2) 0.376
Prosthetic AVAi,
cm2/m2 (SD)
1.1 (0.3) 1.0 (0.3) 0.21
P-PM, n (%) 4 (16) 12 (48) 0.015
Aortic
regurgitation
0.261
Grade 0, n (%) 4 (16) 4 (16)
Grade 1þ, n (%) 19 (76) 19 (76)
Grade 2þ, n (%) 2 (8) 0
Grade 3þ, n (%) 0 1 (4)
Grade 4þ, n (%) 0 1 (4)
AVA, aortic valve area; AVAi, indexed aortic valve area; LVOT, left-ventricular
outflow tract; BSA, body surface area; P-PM, prosthesis-patient mismatch; STJ,
sinotubular junction.
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Table 4 Characteristics of those with and without
prosthesis-patient mismatch (AVAi  0.85 cm2/m2)
No P-PM,
n 5 34
P-PM,
n 5 16
P-value
Depth, cm (SD) 1.0 (0.3) 1.1 (0.4) 0.357
Age, years (SD) 82.6 (5.8) 83.3 (6.1) 0.683
Male sex, n (%) 14 (41.2) 10 (62.5) 0.159
Aortic annulus size, cm
(SD)
2.3 (0.2) 2.3 (0.2) 0.659
LVOT size, cm (SD) 2.2 (0.3) 2.0 (0.3) 0.127
STJ size, cm (SD) 2.8 (0.5) 2.8 (0.3) 0.945
Aortic angulation,
degrees (SD)
228.9 (9.9) 226.0 (11.1) 0.366
Biplane LVEF
pre-procedure, %
(SD)
49.1 (14.5) 50.9 (11.6) 0.651
‘Optimal’ implant
position, n (%)
21 (61.8) 4 (25.0) 0.015
AVA, cm2 (SD) 1.9 (0.4) 1.3 (0.2) ,0.001
BMI, kg/m2 24.0 (2.4) 25.1 (3.1) 0.289
BSA, m2 (SD) 1.7 (0.2) 1.8 (0.3) 0.095
AVAi, cm2/m2 (SD) 1.2 (0.2) 0.7 (0.1) ,0.001
AVA, aortic valve area; AVAi, indexed aortic valve area; LVOT, left-ventricular
outflow tract; BSA, body surface area; STJ, sinotubular junction; BMI, body mass
index.
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As expected, depth of implantation influenced the position of
the new prosthetic annular margin visible on contrast fluoroscopy,
which became supra-annular, annular, or infra-annular depending
on final position (Figure 4). ‘Optimal’ implants were achieved in
25/50 cases (50%), with a mean AVAi of 1.07 cm2/m2 and incidence
of P-PM of 16% (4/25). ‘Shallow’ implants (0–5 mm) were seen in
2/50 (4%), with a mean AVAi of 0.69 cm2/m2 (incidence of P-PM
100%) and ‘deep’ (10–15 mm) implants in 20/50 (40%), with a
mean AVAi of 0.99 cm2/m2 (P-PM in 9/20 ¼ 45%). Three of the
50 cases (6%) were ‘very deep’ (.15 mm) with mean AVAi
1.0 cm2/m2 (P-PM in 1/3 ¼ 33.3%). In one case, there was a
valve-in-valve procedure after the first implant was deployed
very deep (19 mm), the second was optimally placed and this
resulted in an optimal AVAi of 1.2 cm2/m2.
Discussion
P-PM is present when the effective orifice area of the inserted
prosthetic valve is too small in relation to body size.1,2 Haemody-
namically, the consequence is to generate higher than expected
gradients through normally functioning prosthetic valves.3 This
study demonstrates for the first time an incidence of P-PM follow-
ing TAVI with the Medtronic-Corevalve bioprosthesis (32%), which
is slightly less than that seen after conventional open AVR with
stented bioprostheses.
The Medtronic-Corevalve device is a long device and allows for
a wide range of implant depths. It does appear, however, that pos-
ition of implantation is important in optimizing the indexed aortic
valve area and hence minimizing the phenomenon of P-PM, with
the prescribed supra-annular position of the bioprosthesis within
the stent-frame achieving optimal haemodynamics and a low inci-
dence of P-PM (16%). It is important to emphasize that the
term ‘supra-annular’—when referring to conventional aortic
valve replacement—describes a prosthesis type that has no stent
material obstructing the outflow area.13 The term ‘supra-annular’,
used here in the context of Corevalve implantation is another
entity, describing the position of the prosthetic valve within the
Corevalve stent frame relative to the native aortic annulus.
Interestingly, optimal position, while related to P-PM, was unrelated
to AVAi and to the individual components of AVAi (AVA and BSA),
suggesting a nonlinear haemodynamic relationship. One might
hypothesize that suboptimal position may influence Corevalve stent
expansion which—in turn—may be nonlinearly related to AVAi.
Importantly in this context, it is not AVAi per se but its lower
threshold of 0.85 cm2/m2 which defines P-PM. Moreover, it is
P-PM rather than the continuous variable of AVAi from which
P-PM is derived that is predictive of adverse outcome after open AVR.
Of note, P-PM was unrelated to small aortic root geometry, with
no relation to annular, LVOT, and STJ dimension. This is perhaps
related to the fact that the Corevalve case selection requires native
aortic valve annuli of 20–27 mm and hence excludes very small
annuli. It appears that the device allows consistent valve area in
both males and females, and over a wide range of annuli.
Figure 3 The relationship between optimal deployment and
prosthesis-patient mismatch. Scatter plot showing indexed
aortic valve area for patients with optimal vs. non-optimal
device final deployment position. Considerably fewer cases of
prosthesis-patient mismatch were seen if final position was
optimal (defined as 5–10 mm from the annulus). There was
only one case of severe prosthesis-patient mismatch seen, in a
case with suboptimal positioning.
Figure 2 Indexed aortic valve area according to annulus size. In
contrast to open aortic valve replacement, there was a lack of
association between aortic annulus size and bioprosthesis
indexed aortic valve area (AVAi), even for smaller (20–21 mm)
annuli; cut-offs for moderate (AVAi  0.85 cm2/m2; n ¼ 15) and
severe (,0.65 cm2/m2; n ¼ 1) prosthesis-patient mismatch
(P-PM) are shown.
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Controversy over the effect of
prosthesis-patient mismatch on clinical
outcomes
Prosthesis-patient mismatch has been the subject of much contro-
versy of late. Vicchio et al.14 recently reported that—in an elderly
cohort—both moderate and severe mismatch had no bearing on
survival, ventricular mass, and quality of life. Similar studies failed
to show its influence on short and long-term survival.15–18
In contrast, Bleiziffer et al.19 reported in a series of 312 patients
(34.3% of whom had P-PM) a significant difference in exercise
capacity measured objectively at follow-up with stress testing, in
favour of those without P-PM. Also recently, Florath et al.20
demonstrated that severe P-PM was an independent risk factor
of survival time.
Several authorities have attributed the apparent discrepancies in
the significance of P-PM to the choice of parameter used to define
this phenomenon.2,19,21 Most discordant studies have identified
P-PM by use of either the in vitro effective orifice area (EOA), pro-
vided by the manufacturer of the prosthesis, or the geometric
orifice area calculated from the internal diameter of the prosthesis
stent, rather than by direct measurements.2 Hence the over-
whelming body of evidence, both historical and contemporary,
supports P-PM as an important determinant of morbidity22,23
and both short and long-term mortality.24–30 One postulates
that the importance of P-PM would hold regardless of the mode
of implantation, although clearly this must be demonstrated in
longitudinal studies of patients following TAVI.
Patient groups susceptible to the effects
of prosthesis-patient mismatch
There is recent evidence that patients under 65 years of age have
more adverse effects from P-PM than older sedentary patients.2,3
This may be indicative of the fact that younger patients have
higher cardiac output requirements, in relation to higher basal
metabolism and increased physical activity, than older individuals.
Younger patients have, by definition, a longer life expectancy and
may thus be exposed to the ‘chronic’ effects of P-PM for a
longer period of time. Moreover, older patients have more fre-
quent and more severe comorbidities that may compete with or
mask the adverse effects of P-PM.
While not relevant to the TAVI population at present, should
the technology demonstrate long-term efficacy, it may be expected
to penetrate younger and more active patient groups. There is
already established evidence that patients with left-ventricular
dysfunction are more susceptible to the adverse effects of even
moderate P-PM.28–30 This represents an important subset of
patients presently undergoing TAVI and it may be that in such
cases—given the data presented in here—one should strive
aggressively for ‘optimal’ implantation.
Prevention of prosthesis-patient
mismatch in open aortic valve
replacement
Studies have demonstrated that the risk of P-PM can be accurately
predicted at the time of AVR from the ‘projected indexed EOA’, by
dividing the normal reference values of EOA for the different
models/sizes of prostheses, by the patient’s body surface area.31
In the case of anticipated P-PM, a different prosthesis, with a
more optimal haemodynamic profile for a particular patient can
be chosen.2,31,32 A more radical solution, particularly for small
annuli, is aortic root enlargement, to accommodate a larger pros-
thesis of the same model of AVR.2,33,34 This has yielded variable
results with some operators reporting no increased surgical risk
and others reporting a slight excess of procedural mortality.33,34
Figure 4 Supra-annular positioning is not always achieved. Fluoroscopic illustration of depth of implantation and its influence on the new
annular position (shown) and indexed aortic valve area. Native annular margin is shown (asterisk), as is depth of inflow portion of device
(dagger). The new bioprosthetic aortic annulus is identified by the dashed line for each case shown. (A) A shallow implant
(depth ¼ 4.7 mm, AVAi ¼ 0.68 cm2/m2)—new valve very supra-annular. (B) An optimal implant (depth ¼ 8.4 mm, AVAi ¼ 1.7 cm2/m2)—
new valve supra-annular. (C) A deep implant (depth ¼ 12.7 mm, AVAi ¼ 1.1 cm2/m2)—new valve annular. (D) A very deep implant
(depth ¼ 18.4 mm, AVAi ¼ 0.7 cm2/m2)—new valve infra-annular.
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Prevention of prosthesis-patient
mismatch in transcatheter aortic valve
implantation
This study showed Medtronic-Corevalve final deployed position to
be associated with P-PM. Deep delivery may preclude complete
expansion of the section of the stent housing the valve. There
were only two cases with a very shallow implant, but both dis-
played P-PM. If this is indeed a true relationship, it might be
explained by the influence of final stent morphology on the func-
tion of the valve prosthesis it carries: the stent frame, when opti-
mally deployed, displays a slight conical configuration in its lower
portion which houses the valve, with a flute like flaring of its prox-
imal (inflow) portion in the LVOT. One observation is that shallow
implants appear to result in a loss of this configuration in favour of
a more cylindrical one, which could theoretically result in the leaf-
lets of the bioprosthesis being pushed closer together, thereby
impeding function. Investigating this relationship is clearly beyond
the scope of this paper but may be borne out in future larger
studies.
Comparison with the published
experience with the Edwards–Sapien
valve
As yet, limited choices exist for choice of TAVI prosthesis, with
only two sizes of prosthesis offered for each of the two transcath-
eter aortic devices in widespread clinical use: the Medtronic-Cor-
evalve and the Edwards–Sapien device.4,6 The Edwards–Sapien
device is a short balloon-expandable device and precise positioning
is mandatory for deployment, with the use of rapid pacing.4 Clavel
et al.35 recently compared haemodynamic performance in a series
of 50 Edwards–Sapien TAVI cases to a matched population of
stented and stentless surgical bioprostheses. They reported that
12% of Edwards–Sapien TAVI cases had no AR on discharge,
80% trivial or mild AR, and 8% moderate AR. Although cross-
series comparisons are especially difficult for this endpoint, we
observed similar results with Medtronic-Corevalve TAVI: no AR
in 16%, trivial or mild AR in 76%, moderate AR in 4%, and more
AR in 4%.
The same study reported improved indexed effective orifice
area and less P-PM with the TAVI device, relative to the surgical
prostheses. Moreover, they found that, whilst for surgical
prostheses P-PM was even greater with smaller annuli, native
annular dimension appeared unrelated to P-PM in TAVI. With
Medtronic-Corevalve, we observed an indexed effective orifice
area of 1+ 0.3 cm2/m2, with a mean transthoracic gradient of
8.1+ 3.3 mmHg and severe P-PM in only 2%, whereas in
Clavel’s series with Edwards–Sapien TAVI, the indexed effective
orifice area on discharge was 0.9+0.26 cm2/m2, with a mean
transthoracic gradient of 10+4 mmHg and severe P-PM in 11%
of cases. It should be noted that these are indirect comparisons
and a direct haemodynamic comparison is an important future
direction.
With the relatively long self-expanding stent-frame of the
Medtronic-Corevalve prosthesis,6 we demonstrate that, although
several positions of prosthesis are feasible, optimization of AVAi
and minimization of P-PM seem to occur within a relatively
narrow window of final placement depth. Some degree of flexi-
bility in positioning exists when the device is partially deployed
and established centres should strive to optimize the final device
position; transoesophageal echocardiography can complement
fluoroscopy to achieve this.36
Even when final deployment is very deep in the left ventricle,
other options exist to improve valve haemodynamic function.
Within our series, we report one case with Medtronic-Corevalve
valve-in-valve at the same sitting and, although this was for
severe paraprosthetic AR, this resulted in an excellent AVAi.
Other operators have dealt with the problem of deep final deploy-
ment with the use of a snare to pull back the deployed device,
although this is more technically challenging and slightly unpredict-
able as the prosthesis is often firmly anchored to the calcified
native leaflets.37 This makes the excessive force required on pull-
back with a snare difficult to regulate.
With regard to paraprosthetic AR (another important com-
ponent of valve haemodynamic function), we found very deep
implantation to be an important factor. Numbers with very deep
implantation, just as with very shallow implantation, were few.
Severe AR ensued since the covered skirt with very deep implan-
tation is situated below the native annulus in this scenario, allowing
blood to regurgitate through the large holes of the uncovered
portion of the stent frame. These holes are designed to preserve
coronary flow if the Medtronic-Corevalve is optimally placed.
The aetiology of paraprosthetic AR is a complex one governed
by multiple factors, which should be the subject of further study.
Conclusion
The clinical relevance of P-PM following TAVI remains unproved
and requires further elucidation in longitudinal series. Neverthe-
less, just as for open AVR, one should strive to reduce this compli-
cation. Its incidence (32% in the series presented here) appears to
compare at least as favourably to that seen following conventional
AVR, and perhaps even more favourably (16%) when device posi-
tioning is ‘optimal’. This study demonstrates that the operator can
significantly influence valve haemodynamic function by differences
in positioning of the Medtronic-Corevalve stent frame.
Study limitations and future indications
This is a small study and its findings and hypotheses generated must
be validated and tested in larger series. Early echocardiography
after a significant intervention may skew haemodynamic results
but, even though the echocardiograms were performed pre-
discharge for this study, one might expect the stent frame dimen-
sions and haemodynamics to have stabilized at this time. It could be
argued that later echocardiography introduces the added confoun-
der of potential valve deterioration, although we have not wit-
nessed this to date. The limited size of the study makes
multivariate analyses difficult. Future studies should probe the clini-
cal relevance of P-PM in the setting of TAVI, the influence of device
design and the impact of the phenomenon on longer-term clinical
outcomes.
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